38 results on '"Rybicki, Lisa A."'
Search Results
2. Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I+N).
3. Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
4. Multiagent Concurrent Chemoradiotherapy for Locoregionally Advanced Squamous Cell Head and Neck Cancer: Mature Results From a Single Institution
5. Maximizing Local Control and Organ Preservation in Stage IV Squamous Cell Head and Neck Cancer With Hyperfractionated Radiation and Concurrent Chemotherapy
6. Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy
7. Absolute lymphocyte count in patients with glioblastoma treated with temozolomide chemoradiation.
8. Infectious complications in multiple myeloma (MM) patients receiving autologous hematopoietic cell transplantation (AutoHCT) in the contemporary era.
9. Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.
10. Long term peripheral neuropathy symptoms in breast cancer survivors.
11. Risk factors for adverse outcomes in solid tumor interhospital transfer patients.
12. Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice.
13. Do patients learn from survivorship care plans?
14. Outcomes of definitive radiotherapy (dRT) and chemo-radiotherapy (dCRT) for loco-regionally confined (LRC) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ).
15. Impact of lifestyle habits on patient-reported concerns among breast cancer survivors
16. Predicting venous thromboembolism in hospitalized cancer patients: a risk assessment tool.
17. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma treated with R-ICE based on dual expression of MYC and BCL2.
18. Prevalence, risk factors and attenuators of patient-reported concerns among breast cancer survivors.
19. Effects of admission (adm) source, time, and provider on inpatient (inpt) oncology (onc) outcomes at the Cleveland Clinic Foundation (CCF).
20. Timing of the survivorship visit and symptom prevalence in breast cancer survivors.
21. Predictors of response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer.
22. The impact of persistent dysphagia (PD) after induction chemotherapy in patients with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ) receiving a tri-modality treatment regimen.
23. Long term outcomes of hairy cell leukemia patients treated with first and subsequent line with purine analog: The Cleveland Clinic experience.
24. The relationship between pathologic nodal disease and residual tumor viability (RV) in patients with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ) receiving induction chemotherapy, surgery, and post-operative chemo-radiotherapy (CRT).
25. The impact of persistent dysphagia (PD) after induction chemotherapy in patients with locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (E/GEJ) receiving a trimodality treatment regimen.
26. The relationship between pathologic nodal disease and residual tumor viability (RV) in patients with locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (E/GEJ) receiving induction chemotherapy, surgery, and postoperative chemoradiotherapy (CRT).
27. Characteristics of patients referred to a community-based palliative care consultation service.
28. The impact of 5-fluorouracil (5FU) dose intensity (DI) on survival outcomes in patients (pts) receiving multimodality therapy for locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
29. A phase II trial of induction epirubicin, oxaliplatin, and flourouracil, surgery and post-operative concurrent cisplatin and fluorouracil chemoradiotherapy (CRT) in patients (pts) with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
30. Symptom clusters and demographic characteristics in advanced cancer.
31. Weight loss in solid tumors: Clinical features and prognostic importance.
32. A phase III randomized trial of two cisplatin-based concurrent chemoradiation (CCRT) regimens for locally advanced head and neck squamous cell carcinoma (LAHNSCC).
33. A retrospective analysis of the role of gefitinib in the definitive management of esophageal/gastroesophageal junction (E/GEJ) cancer.
34. Is there an interaction between epidermal growth factor receptor (EGFR) inhibition and p16-status in patients (pts) with oropharyngeal squamous cell cancer: A retrospective analysis.
35. EEG for evaluation of “chemobrain.”
36. Ocular adnexal lymphoma (OAL)-outcomes for 82 patients (pts) treated at a single center.
37. Correlation between toxicity and outcome after multimodality therapy of locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
38. Relationship between treatment duration and outcomes in patients receiving concurrent chemoradiotherapy (CCRT) and surgery for locoregionally advanced (LRA) esophageal and gastroesophageal junction (E/GEJ) adenocarcinoma (ACA).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.